

Item_Description	Journal	Year of r	Volume	Issue	Case-con 0=contro
A randomised, blinded, trial of clopidogrel	Lancet		348	9038	1
A randomised, blinded, trial of clopidogrel	Lancet	2003	348	9038	1
A randomised, blinded, trial of clopidogrel	Lancet	2004	348	9038	1
A randomised, blinded, trial of clopidogrel	Lancet	2005	348	9038	1
A randomised, blinded, trial of clopidogrel	Lancet	2006	348	9038	1
A randomised, blinded, trial of clopidogrel	Lancet	2007	348	9038	1
A randomised, blinded, trial of clopidogrel	Lancet	2009	348	9038	1
Acarbose for prevention of type 2 diab	Lancet	2002	359	9323	1
Addition of clopidogrel to aspirin in 45	Lancet	2007	366	9497	1
Addition of clopidogrel to aspirin in 45	Lancet	2006	366	9497	1
Adjuvant imatinib mesylate after resec	Lancet	2009	373	9669	1
After FIELD: should fibrates be used to	Lancet	2006	366	9500	1
Aspirin and clopidogrel compared with	Lancet	2004	364	9431	1
Aspirin and clopidogrel compared with	Lancet	2005	364	9431	1
Aspirin and clopidogrel compared with	Lancet	2006	364	9431	1
Aspirin plus dipyridamole versus aspiri	Lancet	2006	367	9523	1
Bevacizumab plus interferon alfa-2a fo	Lancet	2008	370	9605	1
Cardiovascular morbidity and mortality	Lancet	2002	359	9311	1
Cardiovascular morbidity and mortality	Lancet	2003	359	9311	1
Cardiovascular morbidity and mortality	Lancet	2004	359	9311	1
Cardiovascular morbidity and mortality	Lancet	2003	359	9311	1
Cardiovascular morbidity and mortality	Lancet	2004	359	9311	1
Cardiovascular morbidity and mortality	Lancet	2005	359	9311	1
Cardiovascular morbidity and mortality	Lancet	2002	359	9311	1
Cardiovascular outcomes with etoricox	Lancet	2006	368	9549	1
Cardiovascular outcomes with etoricox	Lancet	2007	368	9549	1
Comparative efficacy and acceptability	Lancet	2009	373	9665	1
Comparison of carvedilol and metopro	Lancet	2003	362	9377	1
Comparison of carvedilol and metopro	Lancet	2004	362	9377	1
Comparison of carvedilol and metopro	Lancet	2006	362	9377	1
Comparison of lumiracoxib with napro	Lancet	2004	364	9435	1
Comparison of lumiracoxib with napro	Lancet	2005	364	9435	1
Comparison of methotrexate monothe	Lancet	2008	372	9636	1
COX-2 selective non-steroidal anti-infl.	Lancet	2003	360	9339	1
COX-2 selective non-steroidal anti-infl.	Lancet	2004	360	9339	1
Cyclo-oxygenase-2 inhibitors versus n	Lancet	2004	363	9423	1
Cyclo-oxygenase-2 inhibitors versus n	Lancet	2006	363	9423	1
Donepezil in patients with severe alz	Lancet	2006	367	6516	1
Donepezil in patients with severe alz	Lancet	2007	367	6516	1
Donepezil in patients with severe alz	Lancet	2008	367	6516	1
Durable efficacy of tipranavir-ritonavir	Lancet	2006	368	9534	1
Effect of ACE inhibitor trandolapril on I	Lancet	2002	354	9172	1
Effect of aggressive versus convention	Lancet	2008	357	9256	1
Effect of carvedilol on outcome after r	Lancet	2003	357	9266	1
Effect of carvedilol on outcome after r	Lancet	2007	357	9266	1
Effect of early versus delayed interferc	Lancet	2007	370	9585	1
Effect of fenofibrate on progression of	Lancet	2007	357	9260	1
Effect of fenofibrate on progression of	Lancet	2008	357	9260	1
Effect of fenofibrate on the need for la	Lancet	2008	370	9600	1
Effect of ibuprofen on cardioprotective	Lancet	2004	361	9357	1

Effect of interleukin-6 receptor inhibitor in patients with	Lancet	2008	371	9617	1
Effect of sibutramine on weight maintenance in obese patients	Lancet	2002	356	9248	1
Effectiveness of antipsychotic drugs in patients with schizophrenia	Lancet	2008	371	9618	1
Effects of candesartan in patients with hypertension	Lancet	2003	362	9386	1
Effects of candesartan in patients with hypertension	Lancet	2005	362	9386	1
Effects of candesartan in patients with hypertension	Lancet	2003	362	9386	1
Effects of candesartan in patients with hypertension	Lancet	2005	362	9386	1
Effects of candesartan in patients with hypertension	Lancet	2003	362	9386	1
Effects of cholesterol-lowering with statins in patients with	Lancet	2004	363	9411	1
Effects of long-term fenofibrate therapy in patients with	Lancet	2005	366	9500	1
Effects of long-term fenofibrate therapy in patients with	Lancet	2006	366	9500	1
Effects of pretreatment with clopidogrel in patients with	Lancet	2005	358	9281	1
Effects of pretreatment with clopidogrel in patients with	Lancet	2002	358	9281	1
Effects of the angiotensin-receptor blocker losartan in patients	Lancet	2009	372	9644	1
Effects of the cannabinoid-1 receptor antagonist rimonabant in	Lancet	2006	365	9468	1
Efficacy and safety of balloon kyphoplasty in patients with	Lancet	2009	373	9668	1
Efficacy and safety of intravenous levonorgestrel in patients	Lancet	2002	360	9328	1
Efficacy and safety of sunitinib in patients with metastatic	Lancet	2007	368	9544	1
Efficacy and safety of tenecteplase in patients with acute	Lancet	2002	358	9282	1
Efficacy and safety of TMC125 (etravirine) in patients with	Lancet	2007	370	9581	1
Efficacy and safety of TMC125 (etravirine) in patients with	Lancet	2007	370	9581	1
Efficacy and tolerability of rimonabant in patients with	Lancet	2006	368	9548	1
Efficacy of galantamine in probable and possible Alzheimer's	Lancet	2002	359	9314	1
Efficacy of human papillomavirus (HPV) vaccine in women	Lancet	2009	374	9686	1
Efficacy of human rotavirus vaccine in children	Lancet	2008	370	9601	1
Efficacy of perindopril in reduction of cardiovascular morbidity	Lancet	2003	362	9386	1
Efficacy of perindopril in reduction of cardiovascular morbidity	Lancet	2005	362	9386	1
Efficacy of romiplostim in patients with thrombocytopenia	Lancet	2008	371	9610	1
Ertapenem versus piperacillin/tazobactam in patients with	Lancet	2005	366	9498	1
Ertapenem versus piperacillin/tazobactam in patients with	Lancet	2006	366	9498	1
Ertapenem versus piperacillin/tazobactam in patients with	Lancet	2007	366	9498	1
Ertapenem versus piperacillin/tazobactam in patients with	Lancet	2008	366	9498	1
Extended duration rivaroxaban versus aspirin in patients with	Lancet	2008	372	9632	1
Extended duration rivaroxaban versus aspirin in patients with	Lancet	2009	372	9632	1
Fighting obesity and associated risk factors in patients with	Lancet	2005	365	9468	1
Glucose metabolism in patients with type 2 diabetes	Lancet	2007	359	9324	1
Intensive oral antiplatelet therapy for patients with acute	Lancet	2009	371	9621	1
Interventional versus conservative treatment of acute	Lancet	2002	360	9335	1
Lessons from MATCH for future randomised controlled trials	Lancet	2006	364	9431	1
Liraglutide once a day versus exenatide in patients with	Lancet	2009	374	9683	1
Liraglutide versus glimepiride monotherapy in patients with	Lancet	2009	373	9662	1
Micafungin versus liposomal amphotericin B in patients with	Lancet	2007	369	9572	1
MRC/BHF Heart Protection Study of cholesterol treatment in	Lancet	2004	360	9326	1
MRC/BHF Heart Protection Study of cholesterol treatment in	Lancet	2008	360	9326	1
MRC/BHF Heart Protection Study of cholesterol treatment in	Lancet	2002	360	9326	1
MRC/BHF Heart Protection Study of cholesterol treatment in	Lancet	2003	361	9374	1
MRC/BHF Heart Protection Study of cholesterol treatment in	Lancet	2004	361	9374	1
Negative pressure wound therapy after lower limb amputation	Lancet	2008	366	9498	1
Non-steroidal anti-inflammatory drugs in patients with	Lancet	2002	359	9301	1
Once-daily atazanavir/ritonavir versus zidovudine/zalcitabine	Lancet	2008	372	9639	1
Outcomes in hypertensive patients at high cardiovascular risk	Lancet	2004	363	9426	1
Postoperative fondaparinux versus placebo in patients with	Lancet	2002	359	9319	1

Postoperative fondaparinux versus pre Lancet	<u>2005</u>	359	9319	1
Postoperative fondaparinux versus pre Lancet	2002	359	9319	1
Prasugrel compared with clopidogrel ir Lancet	2009	373	9665	1
Prevention of cardiovascular events wi Lancet	2005	366	9489	1
Prevention of cardiovascular events wi Lancet	<u>2007</u>	366	9489	1
Prevention of coronary and stroke eve Lancet	2003	361	9364	1
Prevention of coronary and stroke eve Lancet	2004	361	9364	1
Prevention of coronary and stroke eve Lancet	2005	361	9364	1
Prevention of coronary and stroke eve Lancet	2006	361	9364	1
Prevention of coronary and stroke eve Lancet	2007	361	9364	1
Primary prevention of cardiovascular c Lancet	2005	364	9435	1
Primary prevention of cardiovascular c Lancet	2007	364	9435	1
Primary prevention of cardiovascular c Lancet	2004	364	9435	1
Randomised double-blind placebo-cont Lancet	2009	352	9139	1
Randomised trial of effect of alendrona Lancet	2004	348	9041	1
Randomised trial of effect of alendrona Lancet	2006	348	9041	1
Rasagiline as an adjunct to levodopa ii Lancet	2006	365	9463	1
Risk of acute myocardial infarction anc Lancet	2005	365	9458	1
Risk of acute myocardial infarction anc Lancet	2006	365	9458	1
Rivaroxaban versus enoxaparin for thr Lancet	2009	373	9676	1
Roflumilast in symptomatic chronic ob Lancet	2009	374	9691	1
Rosiglitazone evaluated for cardiovasc Lancet	2009	373	9679	1
Safety and efficacy of raltegravir-base Lancet	2009	374	9692	1
Secondary prevention of macrovasculæ Lancet	2005	366	9493	1
Secondary prevention of macrovasculæ Lancet	2007	366	9493	1
Secondary prevention of macrovasculæ Lancet	2009	366	9493	1
Survival and safety of exemestane ver Lancet	2007	369	9561	1
The efficacy and safety of enoxaparin · Lancet	2008	369	9570	1
Treatment of patients with mildly sym Lancet	2009	371	9630	1
Treatment of patients with mildly sym Lancet	2008	371	9630	1
Validation and refinement of scores to Lancet	2008	369	9558	1
Valsartan in a Japanese population wit Lancet	2007	369	9571	1
Voriconazole versus a regimen of amp Lancet	2008	366	9495	1
Amer-Wahlin I et al Lancet	<u>2005</u>	358	9281	0
Amer-Wahlin I et al Lancet	2002	358	9281	0
Ananworanich Lancet	2006	368	9534	0
ART Lancet	<u>2005</u>	362	9386	0
ART Lancet	2003	362	9386	0
ATAC Lancet	2007	359	9324	0
Bobat Lancet	2005	366	9500	0
Bobat Lancet	2006	366	9500	0
Bresson Lancet	2006	367	9523	0
Bretzel Lancet	2008	371	9618	0
Bulkmans Lancet	2008	370	9601	0
Burns Lancet	2005	365	9468	0
Chadwick D et al Lancet	2002	354	9172	0
Chi Lancet	<u>2008</u>	370	9600	0
Cleland Lancet	2003	362	9377	0
Cleland Lancet	2004	362	9377	0
Cleland Lancet	2006	362	9377	0
Cohen Lancet	2008	371	9610	0
Collaborative Group on Hormonal Fact Lancet	2002	360	9328	0

Collet	Lancet	2008	357	9256	0
Comi	Lancet	2009	371	9630	0
Comi	Lancet	2008	371	9630	0
COMMIT	Lancet	2007	366	9497	0
COMMIT	Lancet	2006	366	9497	0
Contant	Lancet	2008	370	9605	0
CTT	Lancet	2005	366	9493	0
CTT	Lancet	2007	366	9493	0
CTT	Lancet	2009	366	9493	0
Danaei	Lancet	2006	368	9548	0
Dickstein K et al	Lancet	2002	360	9335	0
Ellis	Lancet	2009	373	9676	0
Fabbri	Lancet	2009	374	9691	0
Farkouh	Lancet	2004	364	9435	0
Farkouh	Lancet	2005	364	9435	0
Gauderman	Lancet	2007	369	9561	0
Glioma Meta-analysis Trialists Group	Lancet	2003	359	9311	0
Glioma Meta-analysis Trialists Group	Lancet	2004	359	9311	0
Glioma Meta-analysis Trialists Group	Lancet	2005	359	9311	0
Glioma Meta-analysis Trialists Group	Lancet	2002	359	9311	0
Goodman	Lancet	2009	373	9665	0
Grassly	Lancet	2008	369	9570	0
Greenman	Lancet	2008	366	9498	0
Griffiths	Lancet	2007	369	9572	0
Grulich	Lancet	2007	370	9581	0
Gu	Lancet	2006	365	9468	0
Heart Protection Study Collaborative G	Lancet	2004	360	9326	0
Heart Protection Study Collaborative G	Lancet	2008	360	9326	0
Heart Protection Study Collaborative G	Lancet	2002	360	9326	0
Heerspink	Lancet	2009	373	9668	0
Henry	Lancet	2004	361	9357	0
Jabre	Lancet	2009	374	9686	0
Kang	Lancet	2004	363	9411	0
Kappos	Lancet	2009	352	9139	0
Khan	Lancet	2006	367	6516	0
Khan	Lancet	2007	367	6516	0
Khan	Lancet	2008	367	6516	0
Lakha	Lancet	2006	368	9549	0
Lakha	Lancet	2007	368	9549	0
Lantieri	Lancet	2008	372	9639	0
Llovet JM et al	Lancet	2002	359	9319	0
Madruca	Lancet	2007	370	9581	0
Masip J et al	Lancet	2002	356	9248	0
McCarey	Lancet	2004	363	9426	0
McNally	Lancet	2007	369	9571	0
Mega	Lancet	2009	374	9683	0
Michels	Lancet	2004	348	9041	0
Michels	Lancet	2006	348	9041	0
Moller AM et al	Lancet	2002	359	9301	0
Moore	Lancet	2006	366	9500	0
MRC oesophageal cancer working part	Lancet	2005	359	9319	0
MRC oesophageal cancer working part	Lancet	2002	359	9319	0

Myles	Lancet	2004	363	9423	0
Myles	Lancet	2006	363	9423	0
Neth O et al	Lancet	2002	358	9282	0
Pfeffer	Lancet	2005	362	9386	0
Pfeffer	Lancet	2003	362	9386	0
Poulter	Lancet	2005	366	9489	0
Poulter	Lancet	2007	366	9489	0
Prospective Studies Collaboration	Lancet	2009	373	9669	0
Rajatnam	Lancet	2009	373	9662	0
Ravishankar	Lancet	2009	373	9679	0
Rigg JRA et al	Lancet	2002	359	9314	0
Righini	Lancet	2009	371	9621	0
Rugenenti	Lancet	2006	365	9463	0
Ruperto	Lancet	2008	372	9636	0
Sabatine	Lancet	2009	374	9692	0
Sankaranarayanan	Lancet	2007	370	9585	0
Sanz	Lancet	2005	365	9458	0
Sanz	Lancet	2006	365	9458	0
Schmitz N et al	Lancet	2002	359	9323	0
Schnabel	Lancet	2009	373	9665	0
Schortgen	Lancet	2007	357	9260	0
Schortgen	Lancet	2008	357	9260	0
Short	Lancet	2006	364	9431	0
Smith	Lancet	2003	361	9364	0
Smith	Lancet	2004	361	9364	0
Smith	Lancet	2005	361	9364	0
Smith	Lancet	2006	361	9364	0
Smith	Lancet	2007	361	9364	0
Soysal	Lancet	2008	366	9495	0
Stephenson	Lancet	2004	364	9431	0
Stephenson	Lancet	2005	364	9431	0
Stephenson	Lancet	2006	364	9431	0
Stiell	Lancet	2003	357	9266	0
Stiell	Lancet	2007	357	9266	0
Strong	Lancet	2008	372	9632	0
Strong	Lancet	2009	372	9632	0
Tkachev	Lancet	2003	362	9386	0
Tkachev	Lancet	2005	362	9386	0
van der Meulen	Lancet	2005	364	9435	0
van der Meulen	Lancet	2007	364	9435	0
van der Meulen	Lancet	2004	364	9435	0
Vivekananthan	Lancet	2003	361	9374	0
Vivekananthan	Lancet	2004	361	9374	0
Vora	Lancet	2007	368	9544	0
Wahlgren	Lancet	2008	369	9558	0
Wallentin	Lancet	2003	362	9386	0
Wallis	Lancet	2003	360	9339	0
Wallis	Lancet	2004	360	9339	0
West of Scotland Coronary Prevention	Lancet	2002	348	9038	0
West of Scotland Coronary Prevention	Lancet	2003	348	9038	0
West of Scotland Coronary Prevention	Lancet	2004	348	9038	0
West of Scotland Coronary Prevention	Lancet	2005	348	9038	0

West of Scotland Coronary Prevention	Lancet	2006	348	9038	0
West of Scotland Coronary Prevention	Lancet	2007	348	9038	0
West of Scotland Coronary Prevention	Lancet	2009	348	9038	0
Windecker	Lancet	2009	372	9644	0
Yang Q et al	Lancet	2002	359	9311	0
Yang Q et al	Lancet	2003	359	9311	0
Yang Q et al	Lancet	2004	359	9311	0
Yokota	Lancet	2008	371	9617	0
Yusuf	Lancet	2005	366	9498	0
Yusuf	Lancet	2006	366	9498	0
Yusuf	Lancet	2007	366	9498	0
Yusuf	Lancet	2008	366	9498	0
5-hydroxytryptamine-receptor antagonist	Lancet Oncol	2005	6	10	1
5-hydroxytryptamine-receptor antagonist	Lancet Oncol	2007	6	10	1
Advances in oral therapy for multiple myeloma	Lancet Oncol	2006	7	4	1
Antivascular therapy of cancer: DMXAA	Lancet Oncol	2004	4	3	1
Chemotherapy for epithelial ovarian cancer	Lancet Oncol	2003	3	9	1
Chemotherapy for epithelial ovarian cancer	Lancet Oncol	2004	3	9	1
CHOP-like chemotherapy plus rituximab	Lancet Oncol	2006	7	5	1
Clinical germline genetic testing for melanoma	Lancet Oncol	2004	5	5	1
Clinical germline genetic testing for melanoma	Lancet Oncol	2005	5	5	1
Comprehensive side-effect profile of aflibercept	Lancet Oncol	2006	7	8	1
Comprehensive side-effect profile of aflibercept	Lancet Oncol	2007	7	8	1
Current uses of isolated limb perfusion	Lancet Oncol	2003	4	7	1
Cutaneous side-effects of kinase inhibitors	Lancet Oncol	2006	6	7	1
Cyclo-oxygenase 2: a pharmacological target	Lancet Oncol	2002	2	9	1
Effect of anastrozole and tamoxifen as adjuvant	Lancet Oncol	2007	9	1	1
Effect of anastrozole and tamoxifen as adjuvant	Lancet Oncol	2008	9	1	1
Effectiveness of switching from adjuvant tamoxifen	Lancet Oncol	2006	7	12	1
Effects of radiotherapy with concomitant fluorouracil	Lancet Oncol	2009	10	5	1
Efficacy and safety of sorafenib in patients with	Lancet Oncol	2009	10	1	1
Efficacy of azacitidine compared with cytarabine	Lancet Oncol	2009	10	3	1
Fludarabine and mitoxantrone followed by	Lancet Oncol	2009	9	4	1
Gastroenteropancreatic neuroendocrine tumours	Lancet Oncol	2008	9	1	1
Increasing incidence of colorectal cancer	Lancet Oncol	2005	6	11	1
Prophylactic quadrivalent human papillomavirus	Lancet Oncol	2005	6	5	1
Safety and efficacy of sunitinib for metastatic	Lancet Oncol	2009	10	8	1
Six versus eight cycles of bi-weekly docetaxel	Lancet Oncol	2008	9	2	1
Skeletal effects of exemestane on bone mineral	Lancet Oncol	2007	8	2	1
Skeletal effects of exemestane on bone mineral	Lancet Oncol	2008	8	2	1
Surgery, brachytherapy, and external-beam	Lancet Oncol	2005	4	4	1
Systematic review of taxane-containing regimens	Lancet Oncol	2004	5	6	1
The Safety and Tolerability of low-dose	Lancet Oncol	2003	4	1	1
Use of 70-gene signature to predict prognosis	Lancet Oncol	2008	8	12	1
An immunohistochemical procedure to predict	Lancet Oncol	2009	10	8	0
Cetuximab plus gemcitabine and cisplatin	Lancet Oncol	2007	9	1	0
Cetuximab plus gemcitabine and cisplatin	Lancet Oncol	2008	9	1	0
Chemotherapy for epithelial ovarian cancer—					
treatment of recurrent disease	Lancet Oncol	2003	3	9	0

Chemotherapy for epithelial ovarian cancer—treatment of recurrent disease	Lancet Oncol	2004	3	9	0
Circulating tumour cells as prognostic	Lancet Oncol	2009	10	3	0
Clinical phenotypes and molecular gen	Lancet Oncol	2006	6	7	0
Current and future developments in the use of temozolomide for the treatment of brain tumours					
Eff ect of nitric-oxide synthesis on tum	Lancet Oncol	2007	8	2	0
Eff ect of nitric-oxide synthesis on tum	Lancet Oncol	2008	8	2	0
Emerging pathways in the developmer	Lancet Oncol	2003	4	1	0
Environmental, genetic, and molecular	Lancet Oncol	2004	5	5	0
Environmental, genetic, and molecular	Lancet Oncol	2005	5	5	0
Fluorescence-guided surgery with 5-ar	Lancet Oncol	2006	7	5	0
Gene copy number for epidermal grow	Lancet Oncol	2005	6	5	0
Genetic predisposition to testicular ger	Lancet Oncol	2004	5	6	0
Incidence and risk of hypertension wit	Lancet Oncol	2008	9	2	0
Inflammatory response	Lancet Oncol	2005	4	4	0
Intrauterine factors and risk of breast	Lancet Oncol	2008	8	12	0
Intrinsic markers of tumour hypoxia ai	Lancet Oncol	2009	9	4	0
Left thoracoabdominal approach versu	Lancet Oncol	2006	7	8	0
Left thoracoabdominal approach versu	Lancet Oncol	2007	7	8	0
Lymphatic mapping in management of	Lancet Oncol	2005	6	11	0
Management of terminal cancer in eld	Lancet Oncol	2004	4	3	0
Plasma osteopontin, hypoxia, and res	Lancet Oncol	2005	6	10	0
Plasma osteopontin, hypoxia, and res	Lancet Oncol	2007	6	10	0
Predicting survival after liver transplar	Lancet Oncol	2009	10	1	0
Radiation-related damage to dentition	Lancet Oncol	2006	7	4	0
Sentinel-lymph-node biopsy as a stagi	Lancet Oncol	2006	7	12	0
Standard-dose versus higher-dose pro	Lancet Oncol	2009	10	5	0
Treatment strategy of limited surgery	Lancet Oncol	2003	4	7	0
Venous thromboembolism in cervical c	Lancet Oncol	2008	9	1	0
250 mcg or 500 mcg interferon beta-1	Lancet Neurol	2009	8	10	1
Cessation versus continuation of 6-mo	Lancet Neurol	2008	6	12	1
Clarifying Lewy-body parkinsonism wit	Lancet Neurol	2005	4	10	1
Clinical interpretation and use of strok	Lancet Neurol	2006	5	7	1
Clinically important drug interactions i	Lancet Neurol	2004	2	8	1
Clinically important drug interactions i	Lancet Neurol	2006	2	8	1
Clinically important drug interactions i	Lancet Neurol	2008	2	8	1
Comparison of subcutaneous interfero	Lancet Neurol	2008	7	10	1
Comparison of subcutaneous interfero	Lancet Neurol	2009	7	10	1
Continuous dopamine-receptor treatm	Lancet Neurol	2006	5	8	1
CSF markers for incipient Alzheimer's	Lancet Neurol	2004	2	10	1
Effect of natalizumab on clinical and r	Lancet Neurol	2009	8	3	1
Efficacy of pramipexole and transderm	Lancet Neurol	2007	6	6	1
Entacapone in the treatment of Parkin	Lancet Neurol	2005	4	6	1
Evidence for use of glatiramer acetate	Lancet Neurol	2005	4	2	1
Glatiramer acetate in multiple sclerosis	Lancet Neurol	2005	4	9	1
Inflammation in Multiple Sclerosis: Th	Lancet Neurol	2003	1	8	1
Intravenous immune globulin (10% ca	Lancet Neurol	2008	7	2	1
Intravenous immune globulin (10% ca	Lancet Neurol	2009	7	2	1

Medium intensity oral anticoagulants v Lancet Ne	2007	6	2	1
Memantine for the treatment of demer Lancet Ne	2003	2	8	1
Memantine for the treatment of demer Lancet Ne	2004	2	8	1
Miglustat for treatment of Niemann-Pi Lancet Ne	2007	6	9	1
Natalizumab treatment for multiple scl Lancet Ne	2007	6	5	1
Oestrogen and attacks of migraine wit Lancet Ne	2006	3	6	1
Oestrogen and attacks of migraine wit Lancet Ne	2007	3	6	1
Oestrogen and attacks of migraine wit Lancet Ne	2009	3	6	1
REGARD: what can we learn from ranc Lancet Ne	2008	7	10	1
Seizure versus syncope Lancet Ne	2006	5	2	1
The Global Stroke Initiative Lancet Ne	2004	3	7	1
Visual hallucinations in the diagnosis o Lancet Ne	2005	4	10	1
Why did NMDA receptor antagonists fa Lancet Ne	2002	1	6	1
Endovascular treatment with angiopla Lancet Ne	2009	8	10	0
Effi cacy of minocycline in patients wit Lancet Ne	2008	6	12	0
Functional MRI in multiple sclerosis: Lancet Ne	2005	4	10	0
Seminar on choreas Lancet Ne	2006	5	7	0
Neuropeptides Lancet Ne	2004	2	8	0
Neuropeptides Lancet Ne	2006	2	8	0
Neuropeptides Lancet Ne	2008	2	8	0
Results of the Stent-Protected Angiopl Lancet Ne	2008	7	10	0
Results of the Stent-Protected Angiopl Lancet Ne	2009	7	10	0
Neurological aspects of spinal-cord re Lancet Ne	2006	5	8	0
Compulsive use of dopamine replacem Lancet Ne	2004	2	10	0
Autologous non-myeloablative haemo Lancet Ne	2009	8	3	0
Eff ect of rivastigmine on delay to dia Lancet Ne	2007	6	6	0
Intake of vitamin E, vitamin C, and ca Lancet Ne	2005	4	6	0
Prevention of in-hospital mortality afte Lancet Ne	2005	4	2	0
Quality of life and its assessment in m Lancet Ne	2005	4	9	0
Intravenous immunoglobulin for chronic inflammatory demyelinating polyradiculoneuropathy: a systematic review Lancet Ne	2003	1	8	0
Imaging of amyloid β in Alzheimer's di Lancet Ne	2008	7	2	0
Imaging of amyloid β in Alzheimer's di Lancet Ne	2009	7	2	0
Heritability of ischaemic stroke in worr Lancet Ne	2007	6	2	0
Post-stroke plastic reorganisation in th Lancet Ne	2003	2	8	0
Post-stroke plastic reorganisation in th Lancet Ne	2004	2	8	0
Clinical features and viral serologies in Lancet Ne	2007	6	9	0
Epilepsy in patients with brain tumour: Lancet Ne	2007	6	5	0
An active and socially integrated lifest Lancet Ne	2006	3	6	0
An active and socially integrated lifest Lancet Ne	2007	3	6	0
An active and socially integrated lifest Lancet Ne	2009	3	6	0
Stenting versus endarterectomy Lancet Ne	2008	7	10	0
The measurement and clinical relevan Lancet Ne	2006	5	2	0
Olfactory testing in parkinsonism Lancet Ne	2004	3	7	0
Multiple sclerosis and birth order Lancet Ne	2005	4	10	0
When should temporal-lobe epilepsy be treated surgically Lancet Ne	2002	1	6	0
30 years' follow up of randomised stud BMJ	2006	330	7485	1

Acceptability of low molecular weight.	BMJ	2006	332	7541	1
Accuracy of Cervico.	BMJ	2008	325	7359	1
Accuracy of reading liquid	BMJ	2007	335	7609	1
Acute coronary syndromes without ST	BMJ	2008	334	7606	1
Acute treatment of moderate	BMJ	2005	330	7490	1
Acute treatment of moderate	BMJ	2007	330	7490	1
Acute treatment of moderate	BMJ	2008	330	7490	1
Angiotensin receptor blockers and myc	BMJ	2005	329	7477	1
Antipsychotics for people with dement	BMJ	2008	337	a602	1
Are selective COX-2 inhibitors	BMJ	2002	324	7349	1
Are selective COX-2 inhibitors	BMJ	2004	324	7349	1
Assessment of independent.	BMJ	2002	325	7358	1
Assessment of independent.	BMJ	2003	325	7358	1
Association between change in high de	BMJ	2009	338	b92	1
B blockers for glaucoma and excess.	BMJ	2003	325	7377	1
Blood pressure control by home monit	BMJ	2004	329	7458	1
Botulinum toxin type A	BMJ	2002	323	7313	1
British Hypertension Society	BMJ	2004	328	7440	1
Collaborative meta-analysis of rando	BMJ	2002	324	7329	1
Collaborative meta-analysis of rando	BMJ	2007	324	7329	1
Cost effectiveness of self monitoring	BMJ	2008	336	7654	1
Diagnosis and management of neurop.	BMJ	2009	339	b3002	1
Diagnosis and treatment of chronic . . .	BMJ	2007	332	7548	1
Differences in outcomes of patients	BMJ	2005	330	7504	1
Do selective cyclo-oxygenase	BMJ	2006	332	7553	1
Do selective cyclo-oxygenase	BMJ	2007	332	7553	1
Drug Points, Metabolic decompensatio	BMJ	2002	324	7348	1
Drug Points, Metabolic decompensatio	BMJ	2003	324	7348	1
Effect of a very low energy diet on	BMJ	2009	339	b4609	1
Effect of combinations of drugs on all	BMJ	2005	330	7499	1
Effect of combinations of drugs on all	BMJ	2006	330	7499	1
Effect on smoking quit rate of telling p	BMJ	2009	336	7644	1
Effectiveness of antipsychotic treatme	BMJ	2006	333	7561	1
Effectiveness of antipsychotic treatme	BMJ	2007	333	7561	1
Effectiveness of antipsychotic treatme	BMJ	2008	333	7561	1
Effects of angiotensin converting enzy	BMJ	2005	329	7470	1
Effects of prematurity	BMJ	2003	306	6881	1
Efficacy and safety of fonaparinux..	BMJ	2006	332	7537	1
Efficacy and safety of fonaparinux..	BMJ	2007	332	7537	1
Efficacy and safety of fonaparinux..	BMJ	2009	332	7537	1
Efficacy and safety of galantamine in r	BMJ	2007	321	7274	1
Efficacy, tolerability, and upper gastro	BMJ	2002	325	7365	1
Efficacy, tolerability, and upper gastro	BMJ	2003	325	7365	1
Efficacy, tolerability, and upper gastro	BMJ	2005	325	7365	1
Fall prevention with supplemental and	BMJ	2009	339	b3692	1
Fatal dysnatraemia caused by.	BMJ	2003	326	7385	1
Fusidic acid cream in the treatment..	BMJ	2002	324	7331	1
Happiness, social networks and health	BMJ	2009	337	a2781	1
Impact of the MTHFR C677T	BMJ	2004	328	7455	1
Impact of the MTHFR C677T	BMJ	2006	328	7455	1
Inhaled glucocorticoides versus	BMJ	2003	326	7390	1
Inhaled glucocorticoides versus	BMJ	2004	326	7390	1

Iron supplementation for unexplained	BMJ	2003	326	7399	1
Monoamine oxidase type B	BMJ	2006	329	7466	1
Montelukast and fluticasone	BMJ	2003	327	7420	1
Montelukast and fluticasone	BMJ	2004	327	7420	1
Montelukast and fluticasone	BMJ	2007	327	7420	1
New point of care.	BMJ	2008	335	7631	1
Newer agents for blood glucose contro	BMJ	2009	338	b1668	1
No cure, no pay	BMJ	2005	330	7502	1
Non-absorbable disaccharides for hepæ	BMJ	2005	328	7447	1
Observational study of upper gastroint	BMJ	2002	325	7365	1
Observational study of upper gastroint	BMJ	2003	325	7365	1
Observational study of upper gastroint	BMJ	2004	325	7365	1
Observational study of upper gastroint	BMJ	2005	325	7365	1
Omega 3 fatty acids and cardiovasculæ	BMJ	2004	328	7430	1
Paracetamol plus ibuprofen for the tre.	BMJ	2009	337	a1302	1
Performance evaluation of a new rapid	BMJ	2009	339	b2955	1
Pregnancy outcome in women before	BMJ	2008	337	a1343	1
Preventing fractures in elderly	BMJ	2004	327	7406	1
Probiotics for treatment of acute.	BMJ	2007	335	7615	1
Probiotics in prevention of antibiotic	BMJ	2004	324	7350	1
Probiotics in prevention of antibiotic	BMJ	2005	324	7350	1
Probiotics in prevention of antibiotic	BMJ	2006	324	7350	1
Probiotics in prevention of antibiotic	BMJ	2007	324	7350	1
Quantifying effect of statins on low.	BMJ	2003	326	7404	1
Quantifying effect of statins on low.	BMJ	2004	326	7404	1
Quantifying effect of statins on low.	BMJ	2005	326	7404	1
Quantifying effect of statins on low.	BMJ	2006	326	7404	1
Quantifying effect of statins on low.	BMJ	2007	326	7404	1
Quantifying effect of statins on low.	BMJ	2009	326	7404	1
Quetiapine and rivastigamine	BMJ	2005	330	7496	1
Randomised crossover trial of transder	BMJ	2002	322	7295	1
Randomised crossover trial of transder	BMJ	2003	322	7295	1
Randomised double blind trial of etoric	BMJ	2006	324	7352	1
Randomized controlled trial for dual	BMJ	2008	321	7274	1
Recent development in inhaled.	BMJ	2005	330	7492	1
Recent development in inhaled.	BMJ	2006	330	7492	1
Recent development in inhaled.	BMJ	2007	330	7492	1
Reduction of bloodstream infections	BMJ	2007	334	7589	1
Risk factors for coronary	BMJ	2002	316	7134	1
Risk factors for coronary	BMJ	2003	316	7134	1
Risk factors for coronary	BMJ	2004	316	7134	1
Risk factors for coronary	BMJ	2005	316	7134	1
Risk of cardiovascular disease and all (BMJ	2009	339	b4731	1
Risk of myocardial infarction in patient	BMJ	2005	330	7504	1
Risk of myocardial infarction in patient	BMJ	2006	330	7504	1
Risk of myocardial infarction in patient	BMJ	2008	330	7504	1
Risk of myocardial infarction in patient	BMJ	2009	330	7504	1
Soft drinks, fructose consumption	BMJ	2008	336	7639	1
Tacrolimus versus	BMJ	2006	331	7520	1
Tight blood pressure control..	BMJ	2002	317	7160	1
Treatment if menorrhagia during..	BMJ	2007	313	7057	1
Treatment of head louse infectation wi	BMJ	2006	330	7505	1

Use of probiotic Lactobacillus preparat	BMJ	2008	335	7610	1
Use of probiotic Lactobacillus preparat	BMJ	2009	335	7610	1
Use of ramipril in preventing stroke	BMJ	2002	324	7339	1
Use of ramipril in preventing stroke	BMJ	2004	324	7339	1
Use of ramipril in preventing stroke	BMJ	2006	324	7339	1
Using a combination inhaler	BMJ	2007	335	7618	1
Using a combination inhaler	BMJ	2008	335	7618	1
Using a combination inhaler	BMJ	2009	335	7618	1
Varenicline and suicidal behavior	BMJ	2009	339	b3805	1
A strategy to reduce cardiovascular dis	BMJ	2003	326	7404	0
A strategy to reduce cardiovascular dis	BMJ	2004	326	7404	0
A strategy to reduce cardiovascular dis	BMJ	2005	326	7404	0
A strategy to reduce cardiovascular dis	BMJ	2006	326	7404	0
A strategy to reduce cardiovascular dis	BMJ	2007	326	7404	0
A strategy to reduce cardiovascular dis	BMJ	2009	326	7404	0
Accumulation of prion protein in tonsil	BMJ	2002	325	7365	0
Accumulation of prion protein in tonsil	BMJ	2003	325	7365	0
Accumulation of prion protein in tonsil	BMJ	2005	325	7365	0
Accuracy of liquid based versus convey	BMJ	2007	335	7609	0
Adequacy and reporting of allocation c	BMJ	2005	330	7499	0
Adequacy and reporting of allocation c	BMJ	2006	330	7499	0
An evaluation of the multidisciplinary a	BMJ	2003	306	6881	0
Assessing the promise of user involve	BMJ	2008	336	7639	0
Association between depression and ai	BMJ	2004	328	7440	0
Breast cancer mortality in Copenhagen	BMJ	2006	330	7485	0
Brief intervention during hospital admi	BMJ	2002	324	7329	0
Brief intervention during hospital admi	BMJ	2007	324	7329	0
Cardiac outcomes in a cohort of adult	BMJ	2009	339	b4731	0
Category of exposure to HIV and age i	BMJ	2007	313	7057	0
Central overweight and obesity in Briti	BMJ	2003	326	7390	0
Central overweight and obesity in Briti	BMJ	2004	326	7390	0
Commentary: Socially or materially m.	BMJ	2006	332	7553	0
Commentary: Socially or materially m.	BMJ	2007	332	7553	0
Comparison of direct and indirect metl	BMJ	2009	339	b2955	0
Comparison of laparoscopic and mini ii	BMJ	2006	333	7561	0
Comparison of laparoscopic and mini ii	BMJ	2007	333	7561	0
Comparison of laparoscopic and mini ii	BMJ	2008	333	7561	0
Conservative management of persiste	BMJ	2002	323	7313	0
Correct use of the Apgar score for resu	BMJ	2004	329	7458	0
Cost effectiveness of nurse delivered €	BMJ	2009	338	b92	0
Country of training and ethnic origin o	BMJ	2006	329	7466	0
Diagnostic evaluation of people with h	BMJ	2009	337	a1302	0
Diagnostic scope of and exposure to p	BMJ	2008	334	7606	0
Does dietary folate intake modify effec	BMJ	2006	331	7520	0
Effect of hepatitis B immunisation in n	BMJ	2006	332	7537	0
Effect of hepatitis B immunisation in n	BMJ	2007	332	7537	0
Effect of hepatitis B immunisation in n	BMJ	2009	332	7537	0
Effect of routine zinc supplementation	BMJ	2004	324	7350	0
Effect of routine zinc supplementation	BMJ	2005	324	7350	0
Effect of routine zinc supplementation	BMJ	2006	324	7350	0
Effect of routine zinc supplementation	BMJ	2007	324	7350	0
Effect on endometrium of long term tr	BMJ	2002	325	7358	0

Effect on endometrium of long term tr	BMJ	2003	325	7358	0
Effects of the Heartbeat Wales prograr	BMJ	2002	316	7134	0
Effects of the Heartbeat Wales prograr	BMJ	2003	316	7134	0
Effects of the Heartbeat Wales prograr	BMJ	2004	316	7134	0
Effects of the Heartbeat Wales prograr	BMJ	2005	316	7134	0
Efficacy of atenolol and captopril in rec	BMJ	2002	317	7160	0
Efficacy of self monitoring of blood glu	BMJ	2008	336	7654	0
Euthanasia and other end of life decisi	BMJ	2009	339	b3002	0
General practitioners' reasons for rem	BMJ	2002	322	7295	0
General practitioners' reasons for rem	BMJ	2003	322	7295	0
Genetic engineering in athletes	BMJ	2008	337	a602	0
Implementation of the Canadian C-Spi	BMJ	2009	339	b3805	0
Improving tuberculosis control through	BMJ	2006	332	7541	0
Injury to the eye	BMJ	2004	328	7430	0
Investigating suspected anaemia	BMJ	2009	338	b1668	0
Is there a north-south divide in social	BMJ	2005	328	7447	0
Leishmaniasis	BMJ	2003	326	7385	0
Long term pharmacotherapy for obesit	BMJ	2008	335	7631	0
Long term results of compression ther	BMJ	2008	335	7610	0
Long term results of compression ther	BMJ	2009	335	7610	0
Mental disorders in prison populations	BMJ	2005	330	7504	0
Mental disorders in prison populations	BMJ	2006	330	7504	0
Mental disorders in prison populations	BMJ	2008	330	7504	0
Mental disorders in prison populations	BMJ	2009	330	7504	0
Metformin, heart failure, and lactic aci	BMJ	2007	335	7618	0
Metformin, heart failure, and lactic aci	BMJ	2008	335	7618	0
Metformin, heart failure, and lactic aci	BMJ	2009	335	7618	0
Monitoring in chronic disease: a ration	BMJ	2005	330	7492	0
Monitoring in chronic disease: a ration	BMJ	2006	330	7492	0
Monitoring in chronic disease: a ration	BMJ	2007	330	7492	0
Mortality data in adult cardiac surgery	BMJ	2005	330	7490	0
Mortality data in adult cardiac surgery	BMJ	2007	330	7490	0
Mortality data in adult cardiac surgery	BMJ	2008	330	7490	0
Neuraminidase inhibitors for preventin	BMJ	2009	339	b4609	0
Offending in psychiatric patients after discharge from medium secure units: prospective national cohort study	BMJ	2004	328	7455	0
Offending in psychiatric patients after discharge from medium secure units: prospective national cohort study	BMJ	2006	328	7455	0
Partial protection of seasonal trivalent	BMJ	2009	339	b3692	0
Participation in screening for cardiovas	BMJ	2003	326	7399	0
Patients, professionalism, and revalida	BMJ	2005	330	7502	0
Patterns in current perioperative pract	BMJ	2006	330	7505	0
Perinatal mortality and other severe a	BMJ	2008	337	a1343	0
Physical activity cost of the school run	BMJ	2005	329	7470	0
Postpartum splinting of ear deformitie:	BMJ	2007	334	7589	0
Potential alternatives to COX 2 inhibitc	BMJ	2002	324	7349	0
Potential alternatives to COX 2 inhibitc	BMJ	2004	324	7349	0
Predicting the "strugglers"	BMJ	2007	332	7548	0

Prevalence of morbidity associated with BMJ	2002	324	7348	0
Prevalence of morbidity associated with BMJ	2003	324	7348	0
Problem solving treatment and group BMJ	2007	321	7274	0
Prognosis of angina with and without BMJ	2003	327	7420	0
Prognosis of angina with and without BMJ	2004	327	7420	0
Prognosis of angina with and without BMJ	2007	327	7420	0
Relation between burden of disease and BMJ	2002	324	7339	0
Relation between burden of disease and BMJ	2004	324	7339	0
Relation between burden of disease and BMJ	2006	324	7339	0
Role of multivitamins and mineral supplements BMJ	2005	330	7496	0
Routine vaccinations and child survival BMJ	2008	321	7274	0
Sleep attacks in patients taking dopamine BMJ	2006	324	7352	0
Supplementation with antioxidants and BMJ	2009	336	7644	0
Suturing versus conservative management BMJ	2008	325	7359	0
Systematic review of long term effects BMJ	2002	325	7365	0
Systematic review of long term effects BMJ	2003	325	7365	0
Systematic review of long term effects BMJ	2004	325	7365	0
Systematic review of long term effects BMJ	2005	325	7365	0
The rational clinical examination in emergency BMJ	2009	337	7281	0
The white paper on public health BMJ	2005	329	7477	0
Time trends in survival and readmission BMJ	2002	324	7331	0
Use of intensive case management to BMJ	2007	335	7615	0
Use of waist circumference to predict BMJ	2005	330	7504	0
Wegener's granulomatosis presenting BMJ	2004	327	7406	0
Young women's accounts of factors influencing BMJ	2003	325	7377	0
A randomised controlled trial evaluating Gut	2009	46	6	1
A randomised controlled trial. Gut	2006	53	11	1
A randomised, double blind.. Gut	2004	50	6	1
A simple method for assessing intestinal Gut	2003	47	4	1
Adalimumab for maintenance Gut	2008	56	9	1
Adalimumab for maintenance treatment Gut	2009	56	9	1
Adalimumab for maintenance treatment Gut	2007	56	9	1
Adalimumab for the treatment of fistula Gut	2009	58	7	1
An Asia-Pacific, double blind, placebo controlled Gut	2003	52	5	1
An Asia-Pacific, double blind. Gut	2004	52	5	1
Channelling bias and the incidence.. Gut	2006	52	9	1
Channelling bias and the incidence Gut	2004	52	9	1
Channelling bias and the incidence of.. Gut	2003	52	9	1
Channelling bias and the incidence. Gut	2005	52	9	1
Clinical presentation, diagnosis Gut	2008	56	1	1
Clinical presentation, diagnosis and local Gut	2007	56	1	1
Combined oral and enema treatment versus Gut	2007	54	7	1
Combined oral and enema treatment.. Gut	2005	54	7	1
Comparison of a low dose polyethylene glycol Gut	2006	44	2	1
Comparison of a low dose polyethylene glycol Gut	2003	44	2	1
Comparison of a low dose polyethylene glycol Gut	2007	44	2	1
Cost effectiveness of peginterferon Gut	2003	52	3	1
Cost of illness Gut	2008	53	10	1
Cure of Helicobacter pylori infection in Gut	2004	53	1	1
Current concepts in the management of Gut	2007	56	6	1
Diagnosing small bowel Crohn's disease Gut	2003	52	10	1
Echo-enhanced ultrasound: a new validation Gut	2005	55	1	1

Effect of a protein and energy dense	Gut	2004	52	10	1
Effect of a protein and energy dense n	Gut	2003	52	10	1
Erosive oesophagitis: outcome of repe	Gut	2002	43	4	1
Food induced stimulation of the.	Gut	2002	46	6	1
Frequency of glucocorticoid	Gut	2005	35	3	1
Frequency of glucocorticoid resistance	Gut	2004	35	3	1
Frequency of glucocorticoid resistance	Gut	2009	35	3	1
Frequency of glucocorticoid.	Gut	2006	35	3	1
High level perinuclear antineutrophil c	Gut	2003	49	5	1
Increased mucosal tumor necrosis..	Gut	2003	51	5	1
Increased mucosal tumour necrosis fa	Gut	2004	51	5	1
Increased mucosal tumour necrosis.	Gut	2005	51	5	1
Increased mucosal tumour necrosis..	Gut	2006	51	5	1
Infliximab for the treatment of pyoder	Gut	2007	55	4	1
Iron, anaemia, and inflammatory bowe	Gut	2006	53	8	1
Isolation of peptides useful for differer	Gut	2003	52	4	1
Lactobacillus acidophilus (strain LB)	Gut	2002	50	6	1
Long-term safety of infliximab for the	Gut	2009	58	4	1
Low dose balsalazide	Gut	2007	49	6	1
Marker antibody expression	Gut	2004	47	4	1
Marker antibody expression stratifies (Gut	2003	47	4	1
Mutations in pattern recongnition	Gut	2007	56	11	1
Neutrophil derived human S100A12	Gut	2006	52	6	1
New serological markers in inflammatc	Gut	2007	56	10	1
NORCCAP (Norwegian colorectal can	Gut	2009	50	5	1
Once daily high dose probiotic therapy	Gut	2004	53	1	1
Once daily versus three times daily	Gut	2009	58	2	1
Oral budesonide as effective.	Gut	2008	41	2	1
Oral budesonide is a..	Gut	2005	41	2	1
Oral budesonide is as effective	Gut	2007	41	2	1
Oral Budesonide is as.	Gut	2004	41	2	1
Predicting response to peginterferon	Gut	2007	56	5	1
Predicting response to peginterferon..	Gut	2008	56	5	1
Prognostic determinants for chronic.	Gut	2005	54	11	1
Prucalopride (Resolor) in the treatmen	Gut	2009	58	3	1
Randomised trial of once or twice	Gut	2009	57	7	1
Randomised trial of once or twice daily	Gut	2008	57	7	1
Report of the working party of the end	Gut	2003	42	2	1
Report of the working party..	Gut	2004	42	2	1
Suppression of haematopoiesis during	Gut	2005	54	7	1
The feasibility of wireless capsule	Gut	2009	58	11	1
Therapy Update: Which 5-ASA	Gut	2005	51	4	1
Use of mesalazine slow release suppos	Gut	2003	42	2	1
A randomised controlled trial of high v	Gut	2007	49	6	0
A randomised, controlled, double blind	Gut	2006	53	11	0
Aberrant p16INK4A and DPC4/Smad4	Gut	2004	50	6	0
Absorption of calcium and magnesium	Gut	2009	46	6	0
Adenovirus-mediated expression of BM	Gut	2007	56	5	0
Adenovirus-mediated expression of BM	Gut	2008	56	5	0
Age and Helicobacter pylori decrease ç	Gut	2002	43	4	0
Analysis of the IBD5 locus and potenti	Gut	2003	52	4	0
Assessment of meal induced gastric ac	Gut	2006	52	9	0

Assessment of meal induced gastric ac	Gut	2004	52	9	0
Assessment of meal induced gastric ac	Gut	2003	52	9	0
Assessment of meal induced gastric ac	Gut	2005	52	9	0
Bone mineral density and nutritional s	Gut	2003	42	2	0
Brain imaging and functional gastroint	Gut	2006	53	8	0
Carbonylation and disassembly of the	Gut	2002	46	6	0
Card15 gene overexpression in monon	Gut	2006	52	6	0
Cholestasis protects the liver from iscl	Gut	2008	56	1	0
Cholestasis protects the liver from iscl	Gut	2007	56	1	0
Comparison of CT colonography, colon	Gut	2009	58	2	0
Concurrent infection with Schistosoma	Gut	2004	53	1	0
Contrast enhanced magnetic resonanc	Gut	2003	52	10	0
Controlled trial of anti-tuberculous che	Gut	2005	35	3	0
Controlled trial of anti-tuberculous che	Gut	2004	35	3	0
Controlled trial of anti-tuberculous che	Gut	2009	35	3	0
Controlled trial of anti-tuberculous che	Gut	2006	35	3	0
Crohn's disease: increased mortality 1	Gut	2007	55	4	0
Durability of HBeAg seroconversion fol	Gut	2003	52	3	0
Elevated plasma osteopontin associate	Gut	2007	56	6	0
Energy expenditure and body composi	Gut	2008	41	2	0
Energy expenditure and body composi	Gut	2005	41	2	0
Energy expenditure and body composi	Gut	2007	41	2	0
Energy expenditure and body composi	Gut	2004	41	2	0
Flares in chronic hepatitis B patients ir	Gut	2005	54	11	0
Flat and depressed colorectal tumours	Gut	2005	51	4	0
Human adult stem cells derived from ε	Gut	2009	58	7	0
Impairment of mitochondrial acetoace	Gut	2007	56	11	0
Increased incidence of non-Hodgkin's l	Gut	2003	47	4	0
Increased platelet depleted plasma 5-I	Gut	2003	52	5	0
Increased platelet depleted plasma 5-I	Gut	2004	52	5	0
Influence of dietary factors on the clin	Gut	2008	53	10	0
Interleukin 18 is a primary mediator o	Gut	2002	50	6	0
KITENIN recruits Dishevelled/PKCδ to	Gut	2009	58	4	0
Macromolecular transport across the r.	Gut	2006	44	2	0
Macromolecular transport across the r.	Gut	2003	44	2	0
Macromolecular transport across the r.	Gut	2007	44	2	0
Measurement of thiopurine methyltran	Gut	2003	49	5	0
Nodular regenerative hyperplasia in pε	Gut	2007	56	10	0
Oesophageal clearance of acid and bile	Gut	2004	53	1	0
PCR detection of Mycobacterium parat	Gut	2003	51	5	0
PCR detection of Mycobacterium parat	Gut	2004	51	5	0
PCR detection of Mycobacterium parat	Gut	2005	51	5	0
PCR detection of Mycobacterium parat	Gut	2006	51	5	0
Perceptual responses in patients with i	Gut	2004	47	4	0
Perceptual responses in patients with i	Gut	2003	47	4	0
Phosphatidylinositol 3-kinase mediate	Gut	2004	52	10	0
Phosphatidylinositol 3-kinase mediate	Gut	2003	52	10	0
Psychological stress induces eosinophi	Gut	2009	58	11	0
Reduced α-defensin expression is asso	Gut	2009	57	7	0
Reduced α-defensin expression is asso	Gut	2008	57	7	0
Reduced mucosal antimicrobial activity	Gut	2008	56	9	0
Reduced mucosal antimicrobial activity	Gut	2009	56	9	0

Reduced mucosal antimicrobial activity	Gut	2007	56	9	0
Response to interferon alfa is hepatitis	Gut	2005	54	7	0
Retarded release phosphatidylcholine I	Gut	2007	54	7	0
Retarded release phosphatidylcholine I	Gut	2005	54	7	0
Stress protein response in human oes	Gut	2003	42	2	0
Stress protein response in human oes	Gut	2004	42	2	0
Vitamin A inhibits pancreatic stellate c	Gut	2005	55	1	0
Water-soluble CO-releasing molecules	Gut	2009	58	3	0
You get what you expect? A critical ap	Gut	2009	50	5	0
Need for large scale randomised..	Heart	2002	84	4	1
Perindopril improves six minute walkin	Heart	2002	88	4	1
Treatment of chronic heart failure with	Heart	2003	89	3	1
N-terminal pro B type.	Heart	2003	89	8	1
N-terminal pro B type natriuretic.	Heart	2004	89	8	1
Cost effectiveness of extended treatm	Heart	2003	89	3	1
Low prevalence of lipid lowering drugs	Heart	2003	88	1	1
Body surface mapping improves early.	Heart	2003	89	9	1
Summary of recommendations on per	Heart	2004	90	6	1
Impact of Nicorandil in Angina	Heart	2004	90	12	1
Impact of Nicorandil in Angina	Heart	2006	90	12	1
Beneficial effects of fluvastatin..	Heart	2005	90	10	1
Irbesartan significantly reduces..	Heart	2005	91	5	1
Three dimensional segmented myocar	Heart	2005	91	10	1
An omega-3 polyunsaturated fatty aci	Heart	2006	85	5	1
An omega-3 polyunsaturated fatty aci	Heart	2007	85	5	1
Systemic aclerosis associated pulmona	Heart	2006	92	7	1
Systemic aclerosis associated pulmona	Heart	2007	92	7	1
Beneficial effects of abciximab	Heart	2006	92	10	1
Time to treatment and the impact.	Heart	2006	91	11	1
Compliance with and effectiveness to	Heart	2006	92	3	1
Compliance with and effectiveness to	Heart	2007	92	3	1
Compliance with and effectiveness to	Heart	2008	92	3	1
Magnitude and consequences.	Heart	2006	92	11	1
Baseline predictors of tolerability.	Heart	2006	84	6	1
Pathologic assessment of the vulnerabl	Heart	2006	90	12	1
Protective effect of an acute oral loadii	Heart	2007	93	6	1
Target lesion revascularisation in patie	Heart	2007	93	6	1
Effects of metoprolol and carvedilol ..	Heart	2007	93	8	1
Renin: friend or foe	Heart	2007	93	9	1
Optimum guidance of complex PCI..	Heart	2007	90	9	1
Highly active antiretroviral therapy	Heart	2007	92	8	1
Long term effects of bosentan therapy	Heart	2007	93	5	1
Adherence to statin treatment	Heart	2008	88	3	1
Clinical indications for genetic.	Heart	2008	94	4	1
Effects of enzyme replacement therap	Heart	2008	94	2	1
Effects of enzyme replacement therap	Heart	2009	94	2	1
Fractional Flow Reserve: a review	Heart	2008	94	7	1
Fractional Flow Reserve: a review	Heart	2009	94	7	1
Long-term safety . . .	Heart	2008	93	8	1
Pulmonary arterial hypertension in adu	Heart	2009	93	6	1
n-3 polyunsaturated fatty	Heart	2009	95	7	1
Safety of myocardial flash-contrast	Heart	2009	94	12	1

Apoptosis: a pivotal event or an epiph Heart	2002	84	4	0
The pNNx files: re-examining a widely Heart	2002	88	4	0
Haemodynamic and catecholamine res Heart	2003	89	3	0
QT dispersion and left ventricular morj Heart	2003	89	8	0
QT dispersion and left ventricular morj Heart	2004	89	8	0
Relation between heart rate, heart rhy Heart	2003	89	3	0
Seasonality of coronary artery deaths Heart	2003	88	1	0
Creatinine clearance and adverse hosp Heart	2003	89	9	0
A comparison of coronary artery stenti Heart	2004	90	6	0
Established and emerging coronary ris Heart	2004	90	12	0
Established and emerging coronary ris Heart	2006	90	12	0
Plasma von Willebrand factor, soluble Heart	2005	90	10	0
Subclinical pulmonary vein narrowing Heart	2005	91	5	0
New aspects of the ventricular septum Heart	2005	91	10	0
Effect of power Doppler and digital sut Heart	2006	85	5	0
Effect of power Doppler and digital sut Heart	2007	85	5	0
Usefulness of transoesophageal echoc: Heart	2006	92	7	0
Usefulness of transoesophageal echoc: Heart	2007	92	7	0
Evaluation of restenosis and extent of Heart	2006	92	10	0
Functional and prognostic implications Heart	2006	91	11	0
Non-invasive evaluation of the myocar Heart	2006	92	3	0
Non-invasive evaluation of the myocar Heart	2007	92	3	0
Non-invasive evaluation of the myocar Heart	2008	92	3	0
Influences of electrocardiographic ischaemi Heart	2006	92	11	0
Ventricular mass and diastolic functio Heart	2006	84	6	0
Plaque stabilisation by systemic and lo Heart	2006	90	12	0
Evidence that pharmacological strateg Heart	2007	93	6	0
Trimetazidine in the prevention of con: Heart	2007	93	6	0
Improving end-of-life care for patients Heart	2007	93	8	0
Consent bias in research: how to avoic Heart	2007	93	9	0
Reflex syncope in children and adolesc Heart	2007	90	9	0
Coronary interventions in the elderly Heart	2007	92	8	0
Prediction of valve prosthesis-patient Heart	2007	93	5	0
Long term efficacy and safety of atorv. Heart	2008	88	3	0
Impact of blood pressure on the Doppl Heart	2008	94	4	0
Outcomes with the use of glycoprotein Heart	2008	94	2	0
Outcomes with the use of glycoprotein Heart	2009	94	2	0
Contraindications to magnetic resonan Heart	2008	94	7	0
Contraindications to magnetic resonan Heart	2009	94	7	0
Variability of NT-proBNP plasma and u Heart	2008	93	8	0
Can atrial fibrillation with a coarse elec Heart	2009	93	6	0
Atrial fibrillation in heart failure: the cl Heart	2009	95	7	0
Women younger than 65 years with di Heart	2009	94	12	0
Efficacy and safety of modafinil JNNP	2002	72	2	1
Efficacy and safety of modafinil JNNP	2005	72	2	1
Efficacy and safety of modafinil JNNP	2006	72	2	1
Efficacy and safety of modafinil JNNP	2007	72	2	1
Differential effects of three interferon JNNP	2002	73	2	1
Differential effects of three interferon JNNP	2003	73	2	1
Differential effects of three interferon JNNP	2006	73	2	1
Differential effects of three interferon JNNP	2008	73	2	1

Neutralising antibodies to interferon. JNNP	2002	73	5	1
Neutralising antibodies to interferon. JNNP	2003	73	5	1
Pramipexole in patients with Parkinson JNNP	2002	72	6	1
Pramipexole in patients with Parkinson JNNP	2003	72	6	1
Pramipexole in patients with Parkinson JNNP	2004	72	6	1
Pramipexole in patients with Parkinson JNNP	2005	72	6	1
Pramipexole in patients with Parkinson JNNP	2006	72	6	1
Pramipexole in patients with Parkinson JNNP	2007	72	6	1
Pramipexole in patients with Parkinson JNNP	2008	72	6	1
Pramipexole in patients with Parkinson JNNP	2009	72	6	1
Respective potencies of Botox and Dys JNNP	2002	72	4	1
Respective potencies of Botox and Dys JNNP	2003	72	4	1
Respective potencies of Botox and Dys JNNP	2004	72	4	1
Respective potencies of Botox and Dys JNNP	2008	72	4	1
Respective potencies of Botox and Dys JNNP	2009	72	4	1
Cholinesterase inhibitor treatment JNNP	2002	72	3	1
A new antiepileptic drug JNNP	2002	72	4	1
Impact of botulinum toxin type A. JNNP	2002	69	2	1
Dual channel deep brain stimulation s JNNP	2002	73	3	1
Dual channel deep brain stimulation s JNNP	2003	73	3	1
Donepezil for cognitive impairments JNNP	2003	72	6	1
Entacapone is beneficial in both fluctu JNNP	2003	74	8	1
Entacapone is beneficial in both fluctu JNNP	2004	74	8	1
Entacapone is beneficial in both fluctu JNNP	2005	74	8	1
Goal setting and attainment in Alzheimer JNNP	2003	73	5	1
Amelioration of spinal myoclonus JNNP	2003	73	4	1
"Cadasil coma": an underdiagnosed ac JNNP	2003	74	2	1
A controlled study comparing visual fu JNNP	2003	74	3	1
Differentiation of dementia with Lewy. JNNP	2003	73	2	1
Differentiation of dementia with Lewy. JNNP	2005	73	2	1
Prevalence and clinical correlates JNNP	2003	59	1	1
Ropinirole in the treatment of restless JNNP	2004	75	1	1
Ropinirole in the treatment of restless JNNP	2005	75	1	1
The relationship between treatment wi JNNP	2004	75	1	1
The relationship between treatment wi JNNP	2006	75	1	1
The longitudinal relation between.. JNNP	2004	74	11	1
The effect of immunomodulatory treat JNNP	2004	75	7	1
The effect of immunomodulatory treat JNNP	2005	75	7	1
The effect of immunomodulatory treat JNNP	2007	75	7	1
The effect of immunomodulatory treat JNNP	2008	75	7	1
The beneficial antispasticity effect.. JNNP	2004	75	11	1
The Parkinson disease sleep JNNP	2004	73	6	1
The Parkinson disease sleep JNNP	2007	73	6	1
Clozapine in drug included psychosis JNNP	2004	75	5	1
Botulinum toxin treatment for lower lir JNNP	2004	57	11	1
A double blind randomised, parallel gr JNNP	2004	64	1	1
A double blind randomised, parallel gr JNNP	2008	64	1	1
Catechol-o-methyltransferase inhibiti JNNP	2005	63	4	1
Malformation risks of anti epileptic JNNP	2005	77	2	1
Intravenous immune globulins in patie JNNP	2005	71	2	1
The long term retention of levetiracet JNNP	2006	77	1	1
Quantification of central motor conduc JNNP	2006	77	3	1

Clinical and neuropsychological follow. JNNP	2006	77	4	1
Clinical and neuropsychological follow. JNNP	2009	77	4	1
A double blind, randomised JNNP	2006	76	5	1
Safety and tolerability of adjunctive.. JNNP	2007	78	9	1
A multicentre longitudinal observation: JNNP	2007	78	5	1
A multicentre longitudinal observation: JNNP	2008	78	5	1
A multicentre longitudinal observation: JNNP	2009	78	5	1
Operative techniques and morbidity. JNNP	2007	77	1	1
Attentional deficits affect. JNNP	2007	77	10	1
Dementia with lewy bodies.. JNNP	2007	78	11	1
Dementia with lewy bodies.. JNNP	2008	78	11	1
Treatment of shoulder pain.. JNNP	2007	78	8	1
Cannabinoids in multiple sclerosis (CA JNNP	2007	76	12	1
Modafinil for daytime JNNP	2007	76	12	1
Longitudinal multimodal imaging JNNP	2008	79	12	1
Cholinesterase inhibitor JNNP	2008	78	10	1
Long-term effects of the concomitant JNNP	2009	80	6	1
Dipyridamole plus aspirin versus aspiri JNNP	2009	79	11	1
New acute and chronic black holes in r JNNP	2009	80	12	1
HLA-DR 15 is associated with female s JNNP	2002	72	2	0
HLA-DR 15 is associated with female s JNNP	2005	72	2	0
HLA-DR 15 is associated with female s JNNP	2006	72	2	0
HLA-DR 15 is associated with female s JNNP	2007	72	2	0
Bladder dysfunction in acute transvers JNNP	2002	73	2	0
Bladder dysfunction in acute transvers JNNP	2003	73	2	0
Bladder dysfunction in acute transvers JNNP	2006	73	2	0
Bladder dysfunction in acute transvers JNNP	2008	73	2	0
Surgical treatment of temporal lobe eř JNNP	2002	73	5	0
Surgical treatment of temporal lobe eř JNNP	2003	73	5	0
Incidence and prediction of falls in Par JNNP	2002	72	6	0
Incidence and prediction of falls in Par JNNP	2003	72	6	0
Incidence and prediction of falls in Par JNNP	2004	72	6	0
Incidence and prediction of falls in Par JNNP	2005	72	6	0
Incidence and prediction of falls in Par JNNP	2006	72	6	0
Incidence and prediction of falls in Par JNNP	2007	72	6	0
Incidence and prediction of falls in Par JNNP	2008	72	6	0
Incidence and prediction of falls in Par JNNP	2009	72	6	0
Blood pressure and risk of headache: : JNNP	2002	72	4	0
Blood pressure and risk of headache: : JNNP	2003	72	4	0
Blood pressure and risk of headache: : JNNP	2004	72	4	0
Blood pressure and risk of headache: : JNNP	2008	72	4	0
Blood pressure and risk of headache: : JNNP	2009	72	4	0
Adaptation of handwriting size under c JNNP	2002	72	3	0
Intensity of rehabilitation: some answe JNNP	2002	72	4	0
Neuronal metabolic changes in the cor JNNP	2002	69	2	0
Long term psychosocial outcomes afte JNNP	2002	73	3	0
Long term psychosocial outcomes afte JNNP	2003	73	3	0
Behavioural disorders, Parkinson's disc JNNP	2003	72	6	0
Post-transplantation HTLV-1 myelopat JNNP	2003	74	8	0
Post-transplantation HTLV-1 myelopat JNNP	2004	74	8	0
Post-transplantation HTLV-1 myelopat JNNP	2005	74	8	0
Relation between medial temporal atrc JNNP	2003	73	5	0

Increased serum concentrations of tissue JN	2003	73	4	0
Dissociation of affective modulation of JN	2003	74	2	0
Hypothesis on the pathophysiology of JN	2003	74	3	0
Progressive ventricular enlargement in JN	2003	73	2	0
Progressive ventricular enlargement in JN	2005	73	2	0
Frontotemporal dementia and Alzheimer JN	2003	59	1	0
Persistence of pain induced by startle JN	2004	75	1	0
Persistence of pain induced by startle JN	2005	75	1	0
Visual command hallucinations in a pa JN	2004	75	1	0
Visual command hallucinations in a pa JN	2006	75	1	0
A variant of multifocal motor neuropat JN	2004	74	11	0
Clinically evidenced unilateral dissociat JN	2004	75	7	0
Clinically evidenced unilateral dissociat JN	2005	75	7	0
Clinically evidenced unilateral dissociat JN	2007	75	7	0
Clinically evidenced unilateral dissociat JN	2008	75	7	0
Demographic and CT scan features rel JN	2004	75	11	0
Apathy in Parkinson's disease JN	2004	73	6	0
Apathy in Parkinson's disease JN	2007	73	6	0
Association between apolipoprotein E ε JN	2004	75	5	0
Reappraisal of Rasmussen's syndrome JN	2004	75	11	0
What is the optimal dose of botulinum JN	2004	64	1	0
What is the optimal dose of botulinum JN	2008	64	1	0
Micrographia in Parkinson's disease: th JN	2005	63	4	0
Sudden unexpected death in epilepsy JN	2005	77	2	0
Clinical study of 222 patients with pur JN	2005	71	2	0
Cortical laminar necrosis related to pro JN	2006	77	1	0
Risk of multiple sclerosis after head in JN	2006	77	3	0
Visuospatial functions in atypical parki JN	2006	77	4	0
Visuospatial functions in atypical parki JN	2009	77	4	0
Homocysteine and related genetic poly JN	2006	76	5	0
Secondary motor disturbances in 101 JN	2007	78	9	0
Improvement of gait by chronic, high (JN	2007	78	5	0
Improvement of gait by chronic, high (JN	2008	78	5	0
Improvement of gait by chronic, high (JN	2009	78	5	0
Expanded motor and psychiatric phen JN	2007	77	1	0
Sleep-disordered breathing after strok JN	2007	77	10	0
Cognitive impairment in Parkinson's di JN	2007	78	11	0
Cognitive impairment in Parkinson's di JN	2008	78	11	0
Abnormalities in cortical and periphera JN	2007	78	8	0
Placebo controlled, randomised, doubl JN	2007	76	12	0
Stimulation of the subthalamic nucleu JN	2007	76	12	0
Poor attentional function predicts cogn JN	2008	79	12	0
Proxy and self-report agreement on th JN	2008	78	10	0
Deep frontal and periventricular age r JN	2009	80	6	0
Abnormalities in the cerebrospinal fluid JN	2009	79	11	0
Proinflammatory cell stress in sporadic JN	2009	80	12	0

1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	2
1	2
1	2
1	1
1	1
1	1
1	1
2	2
2	2
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	2
1	1
1	1
1	1
2	4
1	2
1	1
1	2
1	2
2	2
2	2
1	2
1	4
1	4
1	1
1	1
1	4
2	5
1	1
1	4
1	1
1	1
1	1
1	1
2	1
2	4

1	4
1	1
1	1
1	2
1	2
1	4
2	4
2	4
2	4
2	4
1	1
1	2
1	1
1	1
1	1
2	4
2	4
2	4
2	4
2	4
2	4
1	1
2	4
2	2
1	4
2	4
2	1
1	2
1	2
2	4
2	4
1	4
1	4
1	4
1	4
2	4
2	4
2	4
2	4
2	4
2	4
2	4
2	4
1	2
1	1
1	4
1	4
2	4
1	1
2	4
2	4
1	2
2	2
1	4
1	4

1	2
1	2
2	4
1	1
1	1
2	1
2	1
2	4
1	1
2	4
1	4
1	4
1	4
1	2
1	1
1	1
1	4
2	5
2	5
1	4
2	4
1	4
1	4
2	5
2	4
2	4
2	4
2	4
2	4
2	4
2	4
1	4
1	4
1	4
2	4
2	4
1	4
1	4
2	4
2	4
2	4
2	4
2	4
2	4
2	4
2	5
2	5
1	4
2	1
1	1
2	5
2	5
1	2
1	2
1	2
1	2

1	2
1	2
1	2
1	3
2	4
2	4
2	4
1	1
2	2
2	2
2	2
2	2
1	4
1	4
2	5
2	4
2	5
2	5
1	1
2	4
2	4
1	1
1	1
2	5
2	5
2	2
1	1
1	1
2	1
1	2
1	1
1	1
1	1
2	4
2	1
2	5
1	1
2	1
1	4
1	1
1	1
2	5
2	2
2	2
2	2
2	4
1	2
1	2
2	5

2	5
1	2
2	4

2	2
2	4
2	4
2	5
2	5
2	5
1	1
2	4
2	4
2	2
2	4
2	4
2	4
1	4
1	4
2	5
2	4
2	4
1	4
1	4
2	5
2	5
1	1
1	1
2	5
2	2
2	4
2	4
2	4
1	1
1	1
2	2
2	4
1	1
1	1
2	5
2	5
2	2
2	4
1	1
1	1

1	2
2	5
2	5
1	1
2	2
2	5
2	5
2	5
2	2
2	2
2	4
2	4
2	2
1	4
1	4
2	5
2	5
2	5
2	5
2	5
1	2
1	2
2	4
2	4
2	4
2	1
2	4
2	5
2	5

2	4
2	2
2	2
2	4
2	4
2	4
2	4
2	4
2	2
2	4
2	4
2	4
2	5
2	2
2	5
2	4

2	5
2	4

2	4
2	4
2	4
2	5
1	1
1	1
1	1
2	2
2	2
2	4
2	4
2	2
2	2
2	2
2	4
2	2
1	1
2	2
2	4
2	4
2	4
2	2
2	5
2	4
2	4
2	4
2	4
2	5
2	5
1	2
2	5
2	5
1	4
2	4
2	4
2	4
2	4
2	4
1	1
1	1
1	1
1	1
2	2
2	2
2	2
2	4
2	5
1	4
2	5
2	4
2	4
2	5
2	5

1	1
2	4
1	1
1	1
1	1
2	4
2	4
2	5
2	4
2	4
2	4
2	4
2	4
2	4
2	4
1	4
2	4
2	4
2	2
1	5
2	5
2	5
2	5
2	5
2	4
2	4
2	4
2	4
2	4
2	4
2	4
2	4
1	2
2	1
2	1
1	1
1	1
2	2
2	2
2	2
2	2
2	5
2	2
2	2
2	2
2	2
2	2
2	5
2	5
2	5
2	5
2	5
2	2
2	2
1	2
1	2
1	1

2	1
2	4
2	4
2	4
2	4
2	4
1	2
1	4
2	4
2	4
2	4
2	5
1	4
2	5
2	2
2	5
2	5
2	2
2	2
1	4
1	4
2	4
2	4
2	4
2	4
2	4
2	5
2	5
2	5
2	4
2	4
2	4
2	4
2	4
2	4
2	4
2	4

2	4
---	---

2	4
2	4
2	4
2	5
2	2
2	4
2	2
2	5
2	2
2	2
2	2
2	4

2	4
2	4
1	4
2	4
2	4
2	4
2	4
2	4
2	4
2	4
2	5
2	4
2	5
1	4
1	4
2	4
2	4
2	4
2	4
2	5
2	5
2	4
2	4
2	2
2	5
2	4
1	1
1	4
1	2
2	4
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
2	1
2	1
2	1
2	1
2	4
2	4
1	1
1	1
1	2
1	2
2	2
2	2
1	1
2	1
2	2
2	4

1	1
1	1
1	1
1	4
2	4
2	4
2	4
2	4
2	4
2	4
2	2
2	2
2	2
2	2
2	2
1	1
2	4
2	2
2	2
2	4
1	1
2	4
2	4
2	4
2	4
2	4
1	2
1	2
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
2	4
1	1
1	1
1	1
2	2
2	2
2	4
2	4
2	2
1	1
1	2
1	1
2	4
2	4
2	4
2	4
2	4
2	4
2	2
2	4

2	4
2	4
1	4
1	4
2	4
2	4
2	2
2	4
2	4
2	2
1	1
2	2
2	4
	4
1	2
2	4
2	2
2	1
1	1
1	1
1	1
1	1
1	4
2	4
1	1
1	1
2	2
2	2
2	2
2	1
1	1
1	2
1	2
1	2
2	1
2	1
2	4
1	4
1	4
1	1
2	4
2	4
2	4
2	4
2	4
2	2
2	5
1	1
1	1
2	4
2	4
2	2
2	4
2	4
2	4

2	2
2	2
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	1
1	2
1	2
1	2
1	2
1	2
2	4
2	2
1	2
2	2
2	2
1	2
1	2
1	2
2	1
2	2
2	4
2	1
2	1
2	1
2	4
1	1
1	1
2	4
2	4
2	2
2	4
2	4
2	4
2	4
2	4
2	4
2	1
2	1
2	1
1	1
2	4
1	2
1	2
1	1
2	2
1	1
2	4
2	4

